戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ture is an important indicator of underlying hematologic neoplasm.
2 ape of AdvSM, often found with an associated hematologic neoplasm.
3 identify individuals at risk of developing a hematologic neoplasm.
4 resent promising targets for therapy in Ph(+)hematologic neoplasms.
5 ombocytopenia with susceptibility to diverse hematologic neoplasms.
6 , classification, staging, and monitoring of hematologic neoplasms.
7 ss in other forms of NHL as well as in other hematologic neoplasms.
8 sequencing assay and analyzed 374 samples of hematologic neoplasms.
9 ality, especially in patients with malignant hematologic neoplasms.
10 ther regions that are recurrently mutated in hematologic neoplasms.
11 h patients with indolent lymphoid or myeloid hematologic neoplasms.
12 mes for COVID-19 in vaccinated patients with hematologic neoplasms.
13 ted with a lower, duration-dependent risk of hematologic neoplasms.
14 t a fundamental element in the definition of hematologic neoplasms.
15    Newly diagnosed invasive solid tumors and hematologic neoplasms.
16 ith hypertension and solid tumors, including hematologic neoplasms.
17 s in the surveillance of patients at risk of hematologic neoplasms.
18 ront treatment stratification for these rare hematologic neoplasms.
19 the occupation of the bone marrow niche by 2 hematologic neoplasms.
20 y changes in visit rates among patients with hematologic neoplasms.
21 ity of clinical sequencing for patients with hematologic neoplasms.
22 1) in hematopoietic cell transplantation for hematologic neoplasms.
23 6% prevalence), myeloid disease (15%), or no hematologic neoplasm (14%).
24 paraproteins (31% versus 92%, P = 0.004) and hematologic neoplasms (23% versus 77%, P = 0.02).
25 able paraproteins (31% vs. 92%, P=0.004) and hematologic neoplasms (23% vs. 77%, P=0.02).
26                 Conclusion: In patients with hematologic neoplasms, absorbed doses calculated for bon
27           Patients with SM and an associated hematologic neoplasm (AHN) comprise up to 70% of those i
28 SM (advSM), especially SM with an associated hematologic neoplasm (AHN).
29                           Twenty subtypes of hematologic neoplasms and 24 subtypes of solid tumors we
30 ciency, increased the rate of development of hematologic neoplasms and influenced the disease spectru
31                                Patients with hematologic neoplasms and patients that underwent HSCT,
32 plasm that accounts for 10% of all malignant hematologic neoplasms and that affects terminally differ
33         Non-PGNMID are often associated with hematologic neoplasms and varied prognosis.
34 had systemic mastocytosis with an associated hematologic neoplasm, and 16 had mast-cell leukemia.
35 ine Pim kinases are up-regulated in specific hematologic neoplasms, and play an important role in key
36 es of germline ATM variants in categories of hematologic neoplasms, and, in patients with CLL, we det
37 opment, progress has been most marked in the hematologic neoplasms, both in myeloablative and in nonm
38 ymphocytosis, which are precursor states for hematologic neoplasms but are usually benign and do not
39 ll acute lymphoblastic leukemia (T-ALL) is a hematologic neoplasm characterized by malignant expansio
40 ocytosis (AdvSM) is a rare, KIT D816V-driven hematologic neoplasm characterized by mast cell infiltra
41 f AITL/PTCL-NOS patients develop concomitant hematologic neoplasms (CHN), and a biomarker to predict
42                                        Among hematologic neoplasms, chronic myeloid leukemia (CML) is
43  activity-is associated with a lower risk of hematologic neoplasms compared to other AHAs.
44 idence interval [0.667,0.913]; P < .001) for hematologic neoplasms compared to the reference group.
45        In this cohort study of patients with hematologic neoplasms, documented in-person visit rates
46 nced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation an
47 pic and polytypic, while all 3 patients with hematologic neoplasms had substructure on electron micro
48 ypic and polytypic while all 3 patients with hematologic neoplasms had substructure on electron micro
49 mal populations have been documented in many hematologic neoplasms, including lymphoma, chronic lymph
50 ternational Consensus (IC) classification of hematologic neoplasms is primarily based on input from c
51                            Its role in other hematologic neoplasms is unclear.
52              At diagnosis or relapse of most hematologic neoplasms, malignant cells are often easily
53                             RNA samples from hematologic neoplasms (N = 2606), solid tumors, normal b
54                     Clonal hematopoiesis and hematologic neoplasms often feature somatic ASXL1 varian
55 arrow transplant recipient mice also develop hematologic neoplasms that appear to originate in the bo
56 dvanced systemic mastocytosis comprises rare hematologic neoplasms that are associated with a poor pr
57 tion between hydralazine use and the risk of hematologic neoplasms using Kaplan-Meier analysis and mu
58                  The pooled mortality OR for hematologic neoplasms was 2.14 (95% CI 1.87-2.44, I(2) 2
59          The 16-year cumulative incidence of hematologic neoplasms was lower in the exposure group (1
60 th newly diagnosed invasive solid tumors and hematologic neoplasms were included in the study.
61 rom antibody-mediated radioimmunotherapy for hematologic neoplasms, which then led to Food and Drug A
62    Participants were patients with malignant hematologic neoplasms who developed CS from COVID-19 (CO
63                       Data for patients with hematologic neoplasms who had received at least 1 system
64 nstructed a cohort of 4,702 individuals with hematologic neoplasms who lived >= 2 years after autolog
65 sly advance the field, the classification of hematologic neoplasms will need to be regularly refined
66 apeutic target as an adjunct to treatment of hematologic neoplasms with chemo- and immunotherapy.